Suzanne Kafaja1, Philip J Clements2, Holly Wilhalme3, Chi-Hong Tseng4, Daniel E Furst5, Grace Hyun Kim6, Jonathan Goldin7, Elizabeth R Volkmann8, Michael D Roth9, Donald P Tashkin10, Dinesh Khanna11. 1. UCLA Medical Center, David Geffen School of Medicine at UCLA, Medicine, Los Angeles, California, United States ; skafaja@mednet.ucla.edu. 2. UCLA Medical Center, David Geffen School of Medicine at UCLA, Medicine, Los Angeles, California, United States ; pclements@mednet.ucla.edu. 3. UCLA Medical Center, David Geffen School of Medicine at UCLA, Medicine, Los Angeles, California, United States ; hwilhalme@mednet.ucla.edu. 4. UCLA Medical Center, David Geffen School of Medicine at UCLA, Medicine, Los Angeles, California, United States ; tseng.ch@gmail.com. 5. UCLA Medical Center, David Geffen School of Medicine at UCLA, Medicine, Los Angeles, California, United States ; DEFurst@mednet.ucla.edu. 6. UCLA, Radiological Science, Los Angeles, California, United States ; gracekim@mednet.ucla.edu. 7. UCLA School Of Medicine, Los Angeles, California, United States ; jgoldin@mednet.ucla.edu. 8. University of California Los Angeles David Geffen School of Medicine, 12222, Department of Medicine, Los Angeles, California, United States ; evolkmann@mednet.ucla.edu. 9. UCLA School of Medicine, Department of Medicine, Los Angeles, California, United States ; mroth@mednet.ucla.edu. 10. UCLA School Of Medicine, Los Angeles, California, United States ; dtashkin@mednet.ucla.edu. 11. University of Michigan, Ann Arbor, Michigan, United States ; khannad@umich.edu.
Abstract
OBJECTIVES: To assess the reliability and the minimal clinically important differences (MCID) for FVC% predicted in the Scleroderma Lung Study I and II. METHODS: Using data from SLS I and II (N=300), we evaluated the test-retest reliability for FVC% predicted (FVC%; screening vs. baseline) using intra-class correlation (ICC). MCID estimates at 12 months were calculated in the pooled cohort (SLS-I and II) using 2 anchors: Transition Dyspnea Index (≥change of 1.5 units for improvement and worsening, respectively) and the SF-36 Health Transition question: "Compared to one year ago, how would you rate your health in general now?", where "somewhat better" or "somewhat worse" were defined as the MCID estimates. We next assessed the association of MCID estimates for improvement and worsening of FVC% with patient reported outcomes (PROs) and computer-assisted quantitation of extent of fibrosis (QLF) and of total ILD (QILD) on HRCT. RESULTS: Reliability of FVC%, assessed at a mean of 34 days, was 0.93 for the pooled cohort. The MCID estimates for the pooled cohort at 12 months for FVC% improvement ranged from 3.0 % to 5.3% and for worsening from -3.0% to -3.3%. FVC% improvement by ≥MCID was associated with either statistically significant or numerical improvements in some PROs, QILD, and QLF, while FVC% worsening ≥MCID was associated with statistically significant or numerical worsening of PROs, QILD, and QLF. CONCLUSION: FVC% has acceptable test-retest reliability, and we have provided the MCID estimates for FVC% in SSc-ILD based changes at 12 months from baseline in two clinical trials. Clinical trial registration available at www.clinicaltrials.gov, IDs NCT00004563 and NCT00883129.
OBJECTIVES: To assess the reliability and the minimal clinically important differences (MCID) for FVC% predicted in the Scleroderma Lung Study I and II. METHODS: Using data from SLS I and II (N=300), we evaluated the test-retest reliability for FVC% predicted (FVC%; screening vs. baseline) using intra-class correlation (ICC). MCID estimates at 12 months were calculated in the pooled cohort (SLS-I and II) using 2 anchors: Transition Dyspnea Index (≥change of 1.5 units for improvement and worsening, respectively) and the SF-36 Health Transition question: "Compared to one year ago, how would you rate your health in general now?", where "somewhat better" or "somewhat worse" were defined as the MCID estimates. We next assessed the association of MCID estimates for improvement and worsening of FVC% with patient reported outcomes (PROs) and computer-assisted quantitation of extent of fibrosis (QLF) and of total ILD (QILD) on HRCT. RESULTS: Reliability of FVC%, assessed at a mean of 34 days, was 0.93 for the pooled cohort. The MCID estimates for the pooled cohort at 12 months for FVC% improvement ranged from 3.0 % to 5.3% and for worsening from -3.0% to -3.3%. FVC% improvement by ≥MCID was associated with either statistically significant or numerical improvements in some PROs, QILD, and QLF, while FVC% worsening ≥MCID was associated with statistically significant or numerical worsening of PROs, QILD, and QLF. CONCLUSION: FVC% has acceptable test-retest reliability, and we have provided the MCID estimates for FVC% in SSc-ILD based changes at 12 months from baseline in two clinical trials. Clinical trial registration available at www.clinicaltrials.gov, IDs NCT00004563 and NCT00883129.
Authors: Roland M du Bois; Derek Weycker; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Alex Kartashov; Talmadge E King; Lisa Lancaster; Paul W Noble; Steven A Sahn; Michiel Thomeer; Dominique Valeyre; Athol U Wells Journal: Am J Respir Crit Care Med Date: 2011-09-22 Impact factor: 21.405
Authors: Hyun J Kim; Matthew S Brown; Robert Elashoff; Gang Li; David W Gjertson; David A Lynch; Diane C Strollo; Eric Kleerup; Daniel Chong; Sumit K Shah; Shama Ahmad; Fereidoun Abtin; Donald P Tashkin; Jonathan G Goldin Journal: Eur Radiol Date: 2011-09-17 Impact factor: 5.315
Authors: Dinesh Khanna; Ron D Hays; Andrew B Shreiner; Gil Y Melmed; Lin Chang; Puja P Khanna; Roger Bolus; Cynthia Whitman; Sylvia H Paz; Tonya Hays; Steven P Reise; Brennan Spiegel Journal: Dig Dis Sci Date: 2017-03-01 Impact factor: 3.199
Authors: Dinesh Khanna; Xiaohong Yan; Donald P Tashkin; Daniel E Furst; Robert Elashoff; Michael D Roth; Richard Silver; Charlie Strange; Marcy Bolster; James R Seibold; David J Riley; Vivien M Hsu; John Varga; Dean E Schraufnagel; Arthur Theodore; Robert Simms; Robert Wise; Fredrick Wigley; Barbara White; Virginia Steen; Charles Read; Maureen Mayes; Ed Parsley; Kamal Mubarak; M Kari Connolly; Jeffrey Golden; Mitchell Olman; Barri Fessler; Naomi Rothfield; Mark Metersky; Philip J Clements Journal: Arthritis Rheum Date: 2007-05
Authors: Talmadge E King; Williamson Z Bradford; Socorro Castro-Bernardini; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Eduard Gorina; Peter M Hopkins; David Kardatzke; Lisa Lancaster; David J Lederer; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Robert Sussman; Jeffrey J Swigris; Paul W Noble Journal: N Engl J Med Date: 2014-05-18 Impact factor: 91.245
Authors: Donald P Tashkin; Michael D Roth; Philip J Clements; Daniel E Furst; Dinesh Khanna; Eric C Kleerup; Jonathan Goldin; Edgar Arriola; Elizabeth R Volkmann; Suzanne Kafaja; Richard Silver; Virginia Steen; Charlie Strange; Robert Wise; Fredrick Wigley; Maureen Mayes; David J Riley; Sabiha Hussain; Shervin Assassi; Vivien M Hsu; Bela Patel; Kristine Phillips; Fernando Martinez; Jeffrey Golden; M Kari Connolly; John Varga; Jane Dematte; Monique E Hinchcliff; Aryeh Fischer; Jeffrey Swigris; Richard Meehan; Arthur Theodore; Robert Simms; Suncica Volkov; Dean E Schraufnagel; Mary Beth Scholand; Tracy Frech; Jerry A Molitor; Kristin Highland; Charles A Read; Marvin J Fritzler; Grace Hyun J Kim; Chi-Hong Tseng; Robert M Elashoff Journal: Lancet Respir Med Date: 2016-07-25 Impact factor: 30.700
Authors: Jacopo Ciaffi; Nina M van Leeuwen; Sophie I E Liem; Maarten K Ninaber; Tom W J Huizinga; Jeska K de Vries-Bouwstra Journal: Clin Rheumatol Date: 2020-01-24 Impact factor: 2.980
Authors: Ajay Sheshadri; Amin Alousi; Lara Bashoura; Karen Stolar; Shiva Baghaie; Muhammad H Arain; Laila Noor; Amulya Balagani; Akash Jain; David Blanco; Abel Ortiz; Susan K Peterson; Renee Langhals; Michael Taylor; Alex Stenzler; Rohtesh S Mehta; Uday R Popat; Chitra Hosing; Gabriela Rondon; Fan Shen; Liang Li; Guang-Shing Cheng; David E Ost; Richard E Champlin; Burton F Dickey Journal: Ann Am Thorac Soc Date: 2020-10
Authors: Grace Hyun J Kim; Donald P Tashkin; Pechin Lo; Matthew S Brown; Elizabeth R Volkmann; David W Gjertson; Dinesh Khanna; Robert M Elashoff; Chi-Hong Tseng; Michael D Roth; Jonathan G Goldin Journal: Arthritis Rheumatol Date: 2019-12-26 Impact factor: 10.995
Authors: Lorinda Chung; Cathie Spino; Richard McLain; Sindhu R Johnson; Christopher P Denton; Jerry A Molitor; Virginia D Steen; Robert Lafyatis; Robert W Simms; Suzanne Kafaja; Tracy M Frech; Vivien Hsu; Robyn T Domsic; Janet E Pope; Jessica K Gordon; Maureen D Mayes; Nora Sandorfi; Faye N Hant; Elana J Bernstein; Soumya Chatterjee; Flavia V Castelino; Ali Ajam; Yannick Allanore; Marco Matucci-Cerinic; Michael L Whitfield; Oliver Distler; Ora Singer; Amber Young; Vivek Nagaraja; David A Fox; Daniel E Furst; Dinesh Khanna Journal: Lancet Rheumatol Date: 2020-10-19
Authors: Elizabeth R Volkmann; Donald P Tashkin; Myung Sim; Grace Hyun Kim; Jonathan Goldin; Philip J Clements Journal: J Scleroderma Relat Disord Date: 2018-12-17
Authors: Grace Hyun J Kim; Stephan S Weigt; John A Belperio; Matthew S Brown; Yu Shi; Joshua H Lai; Jonathan G Goldin Journal: Eur Radiol Date: 2019-08-26 Impact factor: 5.315